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Immune thrombocytopenic purpura (ITP) is an
autoimmune disease in which platelets are sensi-
tized with antiplatelet autoantibodies and then
destroyed by the reticuloendothelial system.1
Platelet refractoriness is frequently observed in
patients with ITP, even in patients without history
of transfusion or pregnancy.2 The factors causing
platelet transfusion refractoriness in patients with
hemato-oncologic disorders are disseminated
intravascular coagulation, concurrent intravenous
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Background/Purpose: Immune thrombocytopenic purpura (ITP) is an autoimmune disease. Platelet refrac-
toriness is frequently seen in patients with ITP. Platelets express platelet-specific antigens and human leukocyte
antigens (HLA). Platelet antibodies to platelet-specific antigens and HLA may be present, but HLA antibodies
in patients with ITP have rarely been reported.
Methods: Sera from 44 adult patients with ITP were screened for platelet antibodies by two flow cytometric
assays. In method I, platelets from normal donor platelets were used as target cells to screen both platelet-
specific antibodies and HLA class I antibodies. In method II, the FlowPRA™ Class I Screening Test kit was
used to screen HLA class I antibodies. Fluorescein isothiocyanate (FITC)-conjugated sheep anti-human IgG
Fc was used as the staining reagent in both methods. The negative serum control was from one of the normal
males with AB blood group who had never received a transfusion. Sera from a pool of five highly sensitized
patients were used as the positive control.
Results: Of the 44 sera from patients with ITP, 31 (70.5%) were method I positive, and 28 (63.6%) were
method II positive. There was no significant difference between the results of method I and method II
(p = 0.439). The distribution of the results of these two tests was: both tests positive in 22 sera, method I
positive and method II negative in nine sera, method I negative and method II positive in six sera, and both
tests negative in seven sera. The mean platelet counts of patients with positive (41.0 ± 40.0 × 109/L) and
negative (40.4 ± 26.8 × 109/L) tests by method I did not differ significantly (p = 0.643). The mean platelet
counts of patients with (36.7 ± 31.5 × 109/L) and without (48.1 ± 43.6 × 109/L) HLA class I antibodies did not
differ significantly (p = 0.59).
Conclusion: HLA class I antibodies are frequently found in ITP. The screening of platelet antibodies includ-
ing platelet-specific antibodies and unappreciated HLA class I antibodies is warranted in patients with ITP.
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amphotericin B, splenomegaly, human leukocyte
antigens (HLA) antibodies, platelet-specific anti-
body, active bleeding, and fever.3–7 In patients
with ITP, platelet-specific antibodies that recognize
platelet glycoproteins have been reported.8–11
However, HLA antibodies in patients with ITP have
rarely been reported.
Flow cytometry is a sensitive method for the
detection of platelet antibodies.12–14 Many platelet
antibody tests including flow cytometry have been
used in the detection of platelet antibodies in pa-
tients with ITP.15–17 In this study, we used two flow
cytometric methods to screen platelet-specific anti-




We studied sera from 44 patients with ITP. The
negative serum control was from one of the normal
males with AB blood group who had never received
a transfusion. Sera from a pool of five highly sen-
sitized patients were used as the positive control.
Method I: flow cytometry using donor
platelets as target cells
1. Platelet preparation
We utilized platelets from 10 fresh plateletpheresis
components as target cells to screen platelet anti-
bodies (HLA antibodies and/or platelet-specific
antibodies) in the sera. Platelets were washed twice
with a mixture of phosphate-buffered saline (PBS)
and anticoagulant citrate dextrose solution (ACD)
formula A (Baxter Healthcare Co., Fenwal Division,
Deerfield, IL, USA) (PBS/ACD = 9/1) with pH ad-
justed to 7.0, by centrifugation at 1400g for 5 min-
utes. Washed platelets were pooled. We adjusted
the platelet count to 200 × 109/L with PBS/ACD.
The reagent platelets were prepared on the day of
analysis and were not stored for future use.
2. Antibody test
Equal volumes (50μL) of patients’ sera and pooled
platelets were incubated at 37°C for 30 minutes,
respectively. The cells were then washed twice with
PBS/ACD at 1400g for 5 minutes. The sensitized
platelets were resuspended in 100 μL PBS/ACD
and incubated for 30 minutes in the dark at room
temperature with 10μL fluorescein isothiocyanate
(FITC)-conjugated sheep anti-human IgG Fc (The
Binding Site Ltd., Birmingham, UK). They were
then washed twice in PBS/ACD. We resuspended
the pellet in 200 μL PBS/ACD by shaking the
tubes on a vortex for 15 seconds and promptly
analyzed using flow cytometry (Epics XL, Coulter
Electronics, Hialeah, FL, USA). We analyzed 5000
platelets per test.
A negative reference range was determined by
using sera from never-transfused males. We set the
analysis region with the negative reference range
in the FL1 histogram. Positive results were defined
as any test with the percentage of fluorescence ex-
ceeding the reference range by 3%.18 Negative and
positive control sera were included in each test.
Method II: flow cytometry using FlowPRA kit
The FlowPRA™ Class I Screening Test (One
Lambda Inc., Canoga Park, CA, USA) was used to
screen HLA class I antibodies. FlowPRA Class I 
assays consist of a pool of 30 different bead pre-
parations. Each preparation is coated with HLA
class I antigens purified from one of 30 cell lines.
All common HLA antigens, as well as many rare
HLA antigens, are represented in the pool. Class
I-positive and -negative control sera (One Lambda
Inc.) were included in each test.
Each serum sample and the negative and posi-
tive controls were tested in parallel with FlowPRA
Class I beads. A total of 5μL FlowPRA Class I beads
were mixed with 20 μL serum and then incubated
at 22°C in the dark for 30 minutes. The beads
were then washed twice in 1 mL FlowPRA wash
buffer at 9000g for 2 minutes. A total of 100 μL
of the working FITC-conjugated IgG in the test kit
was added to each test and vortexed to mix. Then,
it was incubated at 22°C in the dark for 30 min-
utes. The samples were then washed with 1 mL
FlowPRA wash buffer twice, and then resuspended
in 0.5 mL of FlowPRA wash buffer. The samples
were analyzed using a XL Coulter flow cytometer.
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We analyzed 5000 beads per test. Results were
recorded as positive when ≥ 3% of Class I beads
exhibited fluorescence above the negative control
and/or a distinct second peak at the positive region
of the histogram.
Statistical analysis
Statistical analysis of the data was performed using
SPSS version 12.0 (SPSS Inc., Chicago, IL, USA).
The platelet counts of patients with positive and
negative tests were compared using the Mann–
Whitney test. The test results of method I and
method II were compared using the McNemar test.
The relationship between the presence of HLA anti-
bodies and prior transfusion history or pregnancy
history was analyzed using the χ2 test. A p value
of less than 0.05 was considered significant.
Results
A total of 44 patients with ITP (28 female, 16 male)
were studied. The median age of the ITP patients
was 53 years (range, 23–90 years). Their sera were
tested for platelet antibodies by methods I and II.
The test results and platelet counts are presented in
the Table. All assays yielded negative results for
negative control sera.
By method I, the 31 serum specimens (70.5%)
yielded positive results. HLA class I antibodies
were detected in the sera of 28 patients (63.6%)
by method II. There was no significant difference
(p = 0.439) between the results of method I and
method II by the McNemar test.
The mean platelet counts of patients with
positive (41.0 ± 40.0 × 109/L) and negative (40.4 ±
26.8× 109/L) tests by method I did not differ 
significantly (p = 0.643). The mean platelet counts
of patients with (36.7 ± 31.5 × 109/L) and without
(48.1±43.6×109/L) HLA class I antibodies did not
differ significantly (p = 0.59).
Among the 28 patients with HLA class I anti-
bodies, 12 patients had a transfusion history and
18 patients were females. The occurrence of HLA
class I antibodies was not significantly correlated
with having a transfusion history (p = 0.333) or
female gender (p = 1.00).
Among the 20 female patients with history 
of pregnancy, 13 (65%) had HLA class I antibod-
ies. The occurrence of HLA class I antibodies in
female patients with ITP was not correlated with
pregnancy (p = 1.00).
Six males and four females without history 
of transfusion and pregnancy had HLA class I 
antibodies.
Discussion
ITP is a heterogeneous autoimmune disorder. ITP
is due to different immune defects in individual
patients. There is evidence of a B-cell disorder, T cell
abnormalities and cytokine abnormalities.19
In the majority of patients, ITP is caused by an
antiplatelet antibody. Viral or bacterial infections
may initiate ITP via molecular mimicry or B-cell
stimulation.20–23 Polyclonal activation of B cells
may result in autoantibodies being formed.24
During B lymphocyte development, antibod-
ies are assembled by random gene segment reas-
sortment to produce a vast number of specificities,
and some of the antibodies are self-reactive.
HLA antibodies in ITP
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Table. Results of platelet antibody screening and platelet counts in 44 patients with immune
thrombocytopenic purpura
Group Method I Method II Number of patients Platelet count (×109/L) p*
I Positive Positive 22 35.5 ± 34.2 –
II Positive Negative 9 54.6 ± 51.4 0.513
III Negative Positive 6 41.0 ± 20.7 0.370
IV Negative Negative 7 39.9 ± 32.8 0.740
*Comparison of each group with group I using the Mann–Whitney test. Method I = flow cytometry using donor platelets as target cells;
Method II = FlowPRA™ Class I screening test.
Interruption of the checkpoints at which the imma-
ture B cells producing autoreactive antibodies are
removed from the circulation will result in an in-
crease in the numbers of autoantibodies.25 Some
patients with immune cytopenia had polyclonal
autoantibodies against platelets, red cells and
granulocytes. The autoantibodies are specific to
their target cells and, as shown by absorption and
elution, do not cross-react. Some ITP cases may be
associated with autoimmune hemolytic anemia or
autoimmune neutropenia.26–28 In our study, HLA
class I antibodies were found in six males and
four females without both transfusion history
and pregnancy history. These observations may be
explained by “polyclonal B cell activation”.
A number of T-cell abnormalities have been
demonstrated in patients with ITP. There are three
main mechanisms by which T cells could be in-
volved in thrombocytopenia in patients with ITP.
First, significantly increased Th1/Th2 ratios may
be related to ongoing immune activation as part
of autoimmunity.29 Second, release of cytokines
interferes with megakaryocyte maturation and/or
platelet release.30 Circulating cytokines may also
influence the interaction between B and T lym-
phocytes causing pre-existing B cells to proliferate
and produce antiplatelet autoantibodies.31 Third,
some patients with active ITP showed platelet
lysis by T cells.32 These mechanisms may explain
a percentage of patients without measurable an-
tiplatelet antibodies in previous reports15,16 and
our study.
The FlowPRA™ test, designed for HLA-specific
IgG antibody detection, is a sensitive test, missing
the least number of specificities.33 The FlowPRA™
test has numerous advantages over the conven-
tional lymphocytotoxicity test. Using FlowPRA™,
several samples can be processed within a 
short time using commercially available beads.
FlowPRA™ has been used for the detection of HLA
antibodies to predict graft rejection in renal trans-
plant recipients.34 The demerits of the FlowPRA™
test are its high cost and the fact that it cannot
differentiate auto- from allo-HLA antibodies.
In conclusion, flow cytometry is a sensitive assay
for detecting the presence of platelet antibodies.
HLA class I antibodies are frequently found in
patients with ITP. Screening for platelet antibodies
including HLA antibodies is warranted in patients
with ITP. Platelet antibodies including unappre-
ciated HLA class I antibodies may contribute to
platelet transfusion refractoriness in patients
with ITP.
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